Stem cells versus exosomes — the difference that matters

A stem cell is a living cell that can divide and differentiate. An exosome is a nanoscale vesicle — roughly 30 to 150 nanometres — that a cell releases, carrying proteins, lipids and nucleic acids. Exosomes are produced by cells but are not cells: nothing in an exosome preparation can divide, engraft or persist. That difference determines the mechanism (signalling rather than replacement), the regulatory route, and the evidence base. Clinic pages that use the two words interchangeably are describing two different things.

What each one is

Stem cells

In aesthetic and reconstructive practice the cells in question are usually mesenchymal stem or stromal cells (MSCs), often obtained from adipose tissue. They are living, nucleated cells capable of division. Interest in them for tissue repair rests on a substantial body of laboratory and animal work demonstrating immunomodulatory, anti-inflammatory and wound-healing effects^[2].

The clinical translation has been slower than the laboratory work. In aesthetic surgery the most developed application is cell-assisted lipotransfer — enriching a fat graft with stromal vascular fraction or adipose-derived cells to improve how much of it survives — and a systematic review of that approach describes it as a promising concept still facing unresolved problems in standardisation and manufacturing compliance^[7].

Exosomes

Exosomes are among the smallest extracellular vesicles, typically described in the 30–150 nanometre range, secreted by most cell types and carrying protein, lipid and nucleic acid cargo that can alter the behaviour of recipient cells^[3]. The aesthetic interest is straightforward: if a stem cell’s useful effects are largely paracrine — that is, mediated by what it secretes rather than by what it becomes — then collecting the secretions may capture the benefit without administering a living cell.

That reasoning is sound enough to justify research, and the mechanistic findings are real. Stem cell-derived exosomes have been shown to reduce matrix metalloproteinase expression and increase collagen and elastin production in models of photoageing^[5], and reviews of dermatological application describe roles across wound repair, ageing and pigmentation^[6]. What the reasoning does not do is transfer a stem cell’s evidence base to an exosome product. They are separate claims requiring separate testing.

Side by side

The word “exosome” is doing unreliable work

There is a practical problem beneath the science. Isolating exosomes cleanly from other extracellular particles is technically demanding, and methods differ between laboratories and suppliers. The International Society for Extracellular Vesicles has now published three editions of its minimum information standards — MISEV2014, MISEV2018 and MISEV2023 — precisely because nomenclature, separation from non-vesicular particles, and characterisation remained obstacles to comparing results across the field^[1].

The consequence for a patient is direct. Two clinics offering “exosome treatment” may be administering materials that differ in source cell, isolation method, vesicle concentration and purity, with no obligation to disclose any of it. A 2025 comprehensive review of aesthetic exosome use identified exactly this — the absence of standardisation in production and application — as the limitation on drawing conclusions from the existing clinical reports^[4].

What this means when you read a clinic page

Three specific tells are worth watching for. A page that cites stem cell research to support an exosome product has skipped a step: the mechanism may be shared, the evidence is not. A page that says “FDA approved” anywhere near either word is making a claim that, for exosomes, corresponds to nothing — the regulatory status page covers what the FDA has actually published. And a page that will not tell you the source of the material — which cells, cultured how, isolated by what method — is withholding the information you would need to compare it to anything.

Written by the Stem Cell Seoul editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-08-30.